BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Finasteride- and dutasteride-containing medicines: suicidal thoughts and behaviours

Active substance: finasteride, Dutasteride

08.05.2025 - PRAC recommendation

Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines

Suicidal thoughts confirmed as side effect of finasteride tablets; no direct link found for dutasteride

Following an EU-wide review of available data on finasteride and dutasteride medicines, EMA’s safety committee, PRAC, has confirmed suicidal ideation (suicidal thoughts) as a side effect of finasteride 1 and 5 mg tablets. The frequency of the side effect is unknown, meaning that it is not possible to estimate it from available data.

04.10.2024 - procedure started

EMA started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviours.

For details regarding the procedure please click on the following link to the European Medicines Agency (EMA):